Gyre Therapeutics, Inc. (NASDAQ:GYRE - Get Free Report) shares saw an uptick in trading volume on Tuesday . 124,977 shares traded hands during mid-day trading, an increase of 7% from the previous session's volume of 116,958 shares.The stock last traded at $8.39 and had previously closed at $7.68.
Wall Street Analyst Weigh In
Separately, Noble Financial assumed coverage on Gyre Therapeutics in a research note on Tuesday, March 11th. They issued an "outperform" rating for the company.
Read Our Latest Stock Analysis on Gyre Therapeutics
Gyre Therapeutics Trading Up 5.5%
The stock's fifty day simple moving average is $8.91 and its 200 day simple moving average is $10.36. The company has a market cap of $788.50 million, a price-to-earnings ratio of 420.50 and a beta of 1.90.
Gyre Therapeutics (NASDAQ:GYRE - Get Free Report) last announced its quarterly earnings data on Friday, May 9th. The company reported $0.03 EPS for the quarter, hitting analysts' consensus estimates of $0.03. Gyre Therapeutics had a negative return on equity of 118.43% and a negative net margin of 84.57%. The firm had revenue of $22.06 million for the quarter, compared to the consensus estimate of $28.40 million.
Institutional Inflows and Outflows
Several hedge funds have recently bought and sold shares of the stock. SBI Securities Co. Ltd. purchased a new stake in shares of Gyre Therapeutics in the 4th quarter valued at approximately $1,225,000. American Century Companies Inc. purchased a new stake in Gyre Therapeutics in the first quarter valued at approximately $184,000. Northern Trust Corp raised its position in Gyre Therapeutics by 9.1% in the fourth quarter. Northern Trust Corp now owns 103,382 shares of the company's stock valued at $1,251,000 after purchasing an additional 8,624 shares during the period. Advantage Alpha Capital Partners LP lifted its stake in Gyre Therapeutics by 54.0% during the first quarter. Advantage Alpha Capital Partners LP now owns 13,663 shares of the company's stock worth $105,000 after purchasing an additional 4,790 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its position in shares of Gyre Therapeutics by 18.7% during the first quarter. Bank of New York Mellon Corp now owns 16,492 shares of the company's stock worth $127,000 after buying an additional 2,596 shares during the period. Hedge funds and other institutional investors own 23.99% of the company's stock.
Gyre Therapeutics Company Profile
(
Get Free Report)
Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.
Read More
Before you consider Gyre Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gyre Therapeutics wasn't on the list.
While Gyre Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
